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Editorial
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Creation of the Swiss group of Pharmacogenomics 
and personalised Therapy (SPT)
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In memory of Prof. Gérard Siest († April 9th, 2016) and in 
honour of his contribution to the creation of SPT
With the development of modern drugs, it quickly became 
apparent that not all individuals respond equally to drug 
therapy. Outcomes can be multiple, ranging from a good 
response to non-efficacy or to the development of adverse 
drug reactions. Differences in response are partly attrib-
uted to various environmental factors and to an individ-
ual’s genetic predisposition as well [1]. The progress of 
molecular sciences has enabled both an improved under-
standing of drug mechanism, and of underlying molecular 
differences between individuals that influence the phar-
macokinetics and pharmacodynamics of drugs. In turn, 
this provides an opportunity to identify individuals who 
will react differently to a given drug based on their genetic 
characteristics. The study of how individuals respond to 
drugs due to their genetic background has been termed 
“pharmacogenetics” or “pharmacogenomics” [1]. Bring-
ing together clinicians and scientists in various fields, 
such as pharmacology, genetics, molecular biology and 
laboratory medicine, pharmacogenomics is a multidisci-
plinary science with great potential to translate findings 
to benefit patients by individualising therapy and provid-
ing new targets for drug development [1].
Combining multiple scientific disciplines and 
research approaches entails the need for a platform 
that is broad enough to be able to address challenges 
and further advance individualised medicine. For this 
reason, the European Society of Pharmacogenomics and 
Personalised Therapy (ESPT; President: Professor Ron 
HN van Schaik, Erasmus University Medical Center Rot-
terdam, The Netherlands) was established to offer the 
opportunity to exchange information and share ideas 
over a broad spectrum of scientific disciplines [2]. The 
aim of the ESPT is to promote “leadership and innova-
tion in science and education to enhance the scientific 
basis and quality of diagnosis and therapy for patients 
throughout the world.” The ESPT welcomes experts from 
various fields of basic molecular and biochemical sci-
ences, to clinically oriented sciences, along with practi-
tioners, such as hospital clinicians, pharmacologists and 
pharmacists. The society emphasizes an informal struc-
ture that allows for personal initiative. For this reason, 
the creation of national pharmacogenomics societies was 
a key vision of the late president of ESPT, Prof. Gérard 
Siest. Today, the ESPT is present throughout most of 
Europe through national societies that serve to organ-
ize and promote pharmacogenomics research. To add to 
this growing number of national efforts, on February 3rd 
2016, a constitution meeting of the Swiss Group of Phar-
macogenomics and personalised Therapy (SPT) was held 
in Bern, Switzerland. The SPT was created by research-
ers who are active in the field of pharmacogenomics as a 
section within the Swiss Society of Clinical Pharmacology 
and Toxicology (SSCPT, then President: Dr. Hugo Kupfer-
schmidt, Tox Info Suisse, Zurich, Switzerland; current 
President: Professor Thierry Buclin, Lausanne University 
Hospital CHUV, Switzerland) and will serve as a Swiss 
national point for the ESPT. As a country investing one of 
the highest percentages of its BDP in science and devel-
opment, Switzerland has a strong commitment to foster-
ing innovation in medical and pharmaceutical sciences. 
In addition, there exists a longstanding university-indus-
try partnership culture that is underpinned by a strong 
base in the pharmaceutical and biotechnology industry. 
Indeed, as a society encouraging dynamic national and 
international activity, ESPT has warmly welcomed the 
creation of the SPT.
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